Laorden, D.; Domínguez-Ortega, J.; Romero, D.; Villamañán, E.; Mariscal-Aguilar, P.; Granda, P.; Quirce, S.; Álvarez-Sala, R.; on behalf of ASMAGRAVE-HULP Group.
Efficacy Assessment of Biological Treatments in Severe Asthma. J. Clin. Med. 2025, 14, 321.
https://doi.org/10.3390/jcm14020321
AMA Style
Laorden D, Domínguez-Ortega J, Romero D, Villamañán E, Mariscal-Aguilar P, Granda P, Quirce S, Álvarez-Sala R, on behalf of ASMAGRAVE-HULP Group.
Efficacy Assessment of Biological Treatments in Severe Asthma. Journal of Clinical Medicine. 2025; 14(2):321.
https://doi.org/10.3390/jcm14020321
Chicago/Turabian Style
Laorden, Daniel, Javier Domínguez-Ortega, David Romero, Elena Villamañán, Pablo Mariscal-Aguilar, Paula Granda, Santiago Quirce, Rodolfo Álvarez-Sala, and on behalf of ASMAGRAVE-HULP Group.
2025. "Efficacy Assessment of Biological Treatments in Severe Asthma" Journal of Clinical Medicine 14, no. 2: 321.
https://doi.org/10.3390/jcm14020321
APA Style
Laorden, D., Domínguez-Ortega, J., Romero, D., Villamañán, E., Mariscal-Aguilar, P., Granda, P., Quirce, S., Álvarez-Sala, R., & on behalf of ASMAGRAVE-HULP Group.
(2025). Efficacy Assessment of Biological Treatments in Severe Asthma. Journal of Clinical Medicine, 14(2), 321.
https://doi.org/10.3390/jcm14020321